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Summary
Background: Inhaled corticosteroids are effective for the treatment of equine asthma but they induce cortisol suppression with potential side effects.
Objectives: To study the efficacy of ciclesonide, an inhaled corticosteroid with an improved safety profile, on lung function, clinical signs related to
airway obstruction, and serum cortisol levels in asthmatic horses exposed to a mouldy hay challenge.
Study design: Cross-over placebo controlled, blinded, randomised experiment.
Methods: Sixteen horses were enrolled in three subsequent dose-titration studies (8 horses/study) to investigate the effects of inhaled ciclesonide
administered for 2 weeks at doses ranging from 450 to 2700 lg twice daily or 3712.5 lg once daily. Systemic dexamethasone (0.066 mg/kg per os)
was our positive control. A placebo group was also studied. Lung function and clinical scores were blindly performed before and after 7 and 14 days of
treatment. Serum cortisol was measured before and after 3, 5, 7, 10, 14 days of treatment as well as 3 and 7 days post treatment.
Results: After 7 days, dexamethasone induced a significant reduction in pulmonary resistance (from 2.5  0.6 at day 0 to 1.1  0.7 cm H2O/L/s),
pulmonary elastance (5.0  2.6 to 1.2  1.0 cm H2O/L), and of the weighted clinical score (14.8  4.7 to 8.0  4.4). Similarly, ciclesonide 1687.5 lg
twice daily significantly improved pulmonary resistance (2.7  1.1 to 1.6  0.8 cm H2O/L/s), pulmonary elastance (5.2  3.1 to 2.2  1.3 cm H2O/L),
and weighted clinical score (13  2.9 to 10.8  4.2). Serum cortisol suppression (<50 nmol/L) systematically occurred with dexamethasone from day 3
of treatment up to day 3 post treatment, but not with ciclesonide at any tested doses. Placebo did not exert any significant beneficial effect.
Main limitations: Experimentally induced asthma exacerbations in horses might respond differently to treatment than naturally occurring
exacerbations.
Conclusions: Inhaled ciclesonide is an effective treatment for horses with equine asthma. Serum cortisol was unaffected by treatment.
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Introduction
Inhaled fluticasone at high doses is as effective as systemic corticosteroids
at preventing exacerbations in severe asthmatic horses according to lung
function parameters and signs of airway obstruction assessed with a
clinical score [1]. However, even high doses of inhaled fluticasone are not
as effective as systemic dexamethasone for the treatment of equine
asthma exacerbations [1]. For this reason, systemically administered
corticosteroids are indicated as the treatment of choice for equine asthma
exacerbations in the most recent ACVIM Consensus Statement on equine
asthma, because of their ability to rapidly improve clinical signs and lung
function in affected horses [2]. Inhaled corticosteroids have the advantage
of being administered locally and at lower doses, potentially reducing side
effects, making them an attractive alternative to systemic corticosteroid.
Administration of inhaled fluticasone, beclomethasone and budesonide
have been tested off-label in asthmatic horses of all severities, with
effective doses ranging from 2 mg once daily to 6 mg twice daily for
fluticasone, 0.5–3.75 mg twice daily for beclomethasone, and 1.8 mg twice
daily for budesonide [1,3–8]. All of the above drugs reduce serum cortisol
levels [1,5,7,9], although this is neither associated with detectable
alterations of the innate and adaptive immune response nor with the
occurrence of severe adverse events [1,10]. Recently, short-term low-dose
inhaled dexamethasone administration has been shown not to induce
cortisol suppression in healthy horses [11], but its efficacy at improving the
lung function of asthmatic horses remains unproven.
Ciclesonide is an inhaled corticosteroid with a low affinity for
glucocorticoid receptors while in its inactive form. For this reason, it is
considered an inhaled corticosteroid with an excellent safety profile.
Ciclesonide enzymatic activation occurs within the lungs and increases the
affinity of the drug for glucocorticoid receptors as much as 100–120 times
[12]. Due to its favourable safety profile, ciclesonide might be a valuable
drug for asthma-affected horses.
We hypothesised that: 1) inhaled ciclesonide effectively controls airway
obstruction during a mouldy hay challenge in asthmatic horses, and that 2)
its use does not reduce serum cortisol levels. Primarily, this study aims to
investigate the effects of different doses of inhaled ciclesonide on the lung
function and clinical signs related to airflow limitation in asthmatic horses in
which controlled disease exacerbations were experimentally induced. The
secondary objective is to assess the safety profile of ciclesonide in asthma-
affected horses, expressed in terms of serum cortisol levels, clinical
adverse events, and alterations in haematology and blood biochemistry.
Materials and methods
Experimental design
Three crossover dose-titration studies were performed in three con-
secutive years. They evaluated the effects of ciclesonide on the lung
function, clinical signs, and selected blood parameters of asthmatic horses
with experimentally induced controlled airway obstruction. The personnel
performing clinical scores, lung function, data reporting, and statistical
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analysis were blinded to the treatment regimen of the horses. Study I was
an explorative dose-titration study aimed at determining the minimal
treatment dose able to reverse airflow obstruction. Study II was designed
to evaluate the effects of increased doses of ciclesonide. Inhalation devices
with two different nozzles (A and B; a nozzle is the component of the
device that regulate the duration of aerosol generation per actuation) were
tested, to investigate whether reducing the duration of aerosol generation
per actuation (more compliant with the increased breathing frequencies
and decreased inspiratory time of asthmatic horses) could affect the
outcomes of the study. Study III investigated the effect of once vs. twice
daily administration of ciclesonide, using devices with the asthma-adapted
nozzle (B).
Eight horses participated in each study. Sample size calculation was
extrapolated from previous reports [4,13,14] where 40–60% significant
reduction in RL (our primary outcome) was induced with inhaled
corticosteroids. The power of the two-way analysis was set at 0.8, alpha
was 0.05, and enrollment ratio was 1. The resulting sample size varied
from two to seven horses per group. As we did not know the magnitude
of the effect of ciclesonide, nor the variability in the horses’ response to
this treatment, eight horses were enrolled in each group. Personalised hay
challenges able to induce a steady degree of airflow obstruction
(DPL>15 cm H2O) in each animal were implemented for 2 weeks before
the beginning of each study (conditioning) and then throughout the study
period (Fig 1). Horses in each study were ranked by lung resistance (RL)
measured during conditioning and divided within that ranking in pairs. Each
pair was randomly assigned to group 1, 2, 3, or 4.
In study I and study II, conditioning was followed by placebo (1 week),
four cycles of treatment (each composed of 2 weeks of treatment, 1-week
post treatment, 1-week washout), and bronchoreversibility tests. In study
III, conditioning was immediately followed by the cycles of treatment;
placebo was administered as one of the four treatments. Treatment
randomisation during the treatment cycles was done respecting the Latin
Square model, where all groups received all treatments at different times.
Treatment order for the four groups was the same in all three studies
(Fig 1). The severity of the respiratory condition was monitored using
validated clinical scores [15,16] by trained operators.
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Fig 1: Study design. CBC, complete blood count; WCS, weighted clinical score; PT, post treatment week; WO, washout week. The Latin Square Model was applied to all
studies.
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Clinical evaluation of the horses, lung function testing [17], broncho-
reversibility testing, and blood sample collection were performed as
reported in Figure 1. Methodological details are available in Supplementary
Item 1. The procedures were performed in accordance with the guidelines
of the Canadian Council on Animal Care. Animals developing life
threatening signs (combination of laboured breathing, anorexia, or other
indications of distress) had to be withdrawn from the study and treated by
the attending clinician as directed by its condition. The study protocols
were approved by the local Ethical Committee (Rech-1490, Rech-1548,
Rech-1594) and conform to the ARRIVE guidelines [18].
Treatments
Inhaled treatments were administered using an inhalation devicea
employed in a previous study [7]. It is composed of a nostril adapter, a
transparent tube (chamber), and a soft mist inhaler core unit based on
Respimat technology (called device hereafter). All horses were trained to
accept the device prior to the study. Actuations were performed at the
beginning of inhalation to maximise drug delivery to the distal airways. The
presence of a respiration indicator (“breath indicator”) located in
the chamber wall of the nostril adapter allowed easy identification of the
breathing phases of the horses by deflection.
Placebo was administered using the same device with cartridges
containing the excipients (anhydrous ethanol, purified water, and
hydrochloric acid) but lacking the active ingredient to be tested. Placebo
and twice daily treatments were administered at approximately 08.00 and
between 16.00 and 18.00. Systemic dexamethasone (0.066 mg/kg once
daily in the morning) served as positive control and was administered
orally mixed with molasses, using a plastic syringe.
In study I, the following treatments were administered using devices
equipped with nozzle A: A) ciclesonide 450 lg (two actuations of
225 lg each) twice daily; B) ciclesonide 900 lg (four actuations) twice
daily; C) ciclesonide 1800 lg (eight actuations) twice daily; D)
dexamethasone.
In study II, the treatments tested were: A) ciclesonide 1687.5 lg (five
actuations of 337.5 lg each) twice daily with device equipped with nozzle
B; B) ciclesonide 2700 lg (eight actuations) twice daily with nozzle A; C)
ciclesonide 2700 lg (eight actuations) twice daily with nozzle B; D)
dexamethasone. The relevant difference between nozzle A and B was the
drug release duration they induced (A: 1.5 s/actuation vs. B: 1.0 s/
actuation).
In study III, the treatments tested were the following, all administered
with devices equipped with nozzle B: A) placebo (0 lg ciclesonide, eight
actuations) twice daily; B) ciclesonide 2700 lg (eight actuations of 337.5 l
each) twice daily; C) ciclesonide 3712.5 lg (11 actuations) once daily in the
morning; D) ciclesonide 3712.5 lg (11 actuations) once daily in the
evening.
Adverse events
Adverse events were defined as any changes in the horse health status
requiring the attention of the attending veterinarian. Variation in the blood
5
CIC 450 µg BID
DEX 0.066 mg/kg SIDCIC 900 µg BID
CIC 1800 µg BID CIC 450 µg BID
DEX 0.066 mg/kg SIDCIC 900 µg BID
CIC 1800 µg BID
4
§ 
§ 
* *
*
* *
§ 
§
§ 
§ 
§ § § 
§ 
*
*
* * *
* *
*
*
*
* *
*
*
*
*
*
*
§ 
§ 
*
0
1
Day 0 
0 
10 
15
5 
0 
Se
ru
m
 c
or
tis
ol
 [n
m
ol
/L
] 
50 
150 
100 
E L
 [c
m
H
2O
/L
] 
R
L [
cm
H
2O
/L
/s
] 
Day 7 Day 14 Day 21
Day 0 Day 7 Day 14 Day 21
Day 
7
Day
14 21
0 3 5 7 10 14 17 21
3
2
0
7.5
7.0
6.5
6.0
5.5
8.0
B
re
at
hi
ng
 e
ff
or
t s
co
re
a) c)
b) d)
Fig 2: Study I. Lung function a)–b), breathing effort scores c), and serum cortisol d) of horses administered inhaled ciclesonide (CIC) at different doses or oral
dexamethasone (DEX). Data are presented as means and s.d. a), b) and d) or medians c) across eight horses at each day. RL, respiratory resistance; EL, respiratory
elastance. §Different from day 0 for the same treatment (P<0.001); *Different from dexamethasone at the same time point (P≤0.003).
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parameters tested were also recorded but not classified as AE when they
occurred in the absence of any clinical sign.
Data analysis
Statistical analysis was performed with SAS software v.9.3b. In studies I and
II, data obtained during the placebo phase were analysed separately using
paired t test. Mixed linear models with horses as random factor were used
to investigate the effect of treatment order and of the cycle of treatment
(that is, whether initial values differed among treatments) on the
parameters studied. A linear mixed model was also used to assess the
effect of time, treatment, and their interaction in each study. A priori
contrasts were performed to compare means of the same treatment at
different time points and to compare means of different treatments at the
same time point. Cochran-Mantel-Haenszel test was employed to analyse
ordinal data (breathing effort score and weighted clinical score). The
association between clinical scores and lung function parameters were
evaluated using linear regression test. Paired t-tests were employed to
evaluate bronchoreversibility data. Additional details on statistical analysis
are available in Supplementary Item 1.
Results
Horses
Details of the horses enrolled in each study are reported in Supplementary
Item 1, together with data on the effect of treatment order and differences
among cycles of treatment.
Study I
Placebo treatment did not alter significantly the breathing effort score, lung
function parameters (DPL, RL, and pulmonary elastance, EL), serum cortisol
levels, or CBC values (data not presented). Dexamethasone significantly
decreased DPL, RL, and EL at day 7 and 14 of treatment. A return to
baseline values was observed 7 days post treatment (day 21) (Fig 2a, b,
and Supplementary Item 2a). Ciclesonide 450 and 900 lg did not
significantly affect DPL, RL, and EL at any time points. Treatments with
1800 lg ciclesonide significantly decreased DPL and EL, but not RL, on days
7 and 14 of treatment but the effect was lost 7 days post treatment (day
21). At day 14, dexamethasone-treated horses had significantly lower
values of RL than horses treated with 450, 900, or 1800 lg ciclesonide and
significantly lower values of EL than horses treated with 450 lg ciclesonide.
Atropine administration significantly reduced DPL, RL, and EL in all horses,
indicating the reversibility of the airway obstruction (Supplementary Item
3a–c). The 8-point breathing effort score was not significantly affected by
the treatments tested (Fig 2c).
Treatments with 450, 900, and 1800 lg of ciclesonide did not alter
significantly serum cortisol over time (days 3, 5, 7, 10, 14, 17, and 21
compared to day 0). During ciclesonide treatment, four horses accounted
for 12 (out of 64) cortisol measures below normal ranges (<50 nmol/L).
Dexamethasone significantly decreased serum cortisol on days 3, 5, 7, 10,
14, (treatment) and 17 (3 days post treatment) compared to day 0. Cortisol
had returned to baseline on day 21 (7 days post treatment). On days 3 to
17, serum cortisol levels were significantly lower in dexamethasone-treated
than in ciclesonide-treated horses (Fig 2d). Ciclesonide did not alter
significantly packed cell volume (PCV), total protein, WBC counts,
segmented neutrophils, or lymphocyte values. Dexamethasone significantly
decreased blood lymphocytes on day 14 and total proteins on day 21
compared to day 0 (Table 1).
Adverse events observed in study I were most frequently represented
by ringworm lesions, observed in 7/8 horses with onset during the
washout week of the first cycle of treatment. No other AE was observed in
>1 horse during ciclesonide treatment. A detailed description of the AE is
available online.
Study II
Placebo treatment did not alter significantly any of the parameters studied
(data not shown). All treatments studied induced a statistically significant
decrease in DPL, RL, and EL at day 7 and day 14 compared to day 0. The
only exceptions were DPL of horses treated with 1687.5 lg of ciclesonide
at day 7 and EL of horses treated with 2700 lg of ciclesonide (nozzle B) at
day 7 (Fig 3a, b, and Supplementary Item 2b). No significant differences
were observed at any time points among the treatments tested. The WCS
significantly decreased with all treatments at day 14. The WCS of horses
treated with dexamethasone and with 2700 lg ciclesonide (nozzle B)
were significantly reduced also at day 7 and day 21 compared to day 0
(Fig 3c). Overall, the 23-point WCS employed predicted DPL, RL, and EL
with r2 values of 0.48, 0.38, and 0.47, respectively. The results of
bronchoreversibility tests performed at the end of study II have been
published previously [19] and showed that all horses responded to the
bronchodilator.
Serum cortisol was significantly lower on day 0 of the first vs. second
(P = 0.01) and third (P = 0.048) cycles of treatment. Only dexamethasone
reduced significantly serum cortisol on days 3 to 17 compared to day 0. On
these days, cortisol values in dexamethasone-treated horses were
significantly lower compared to those of horses receiving other treatments
(Fig 3d). During ciclesonide treatment, one horse accounted for six (out of
64) cortisol measures below normal ranges: one during treatment A (day 5)
and five during B (days 0–10). Overall, PCV and total proteins were
significantly lower in all horses on day 0 of the fourth cycle of treatment
compared to the first (P = 0.006 and P = 0.02, respectively) and second
(P = 0.02 and P = 0.03) ones. Similarly, WBC was lower on day 0 of the
fourth than on the first cycle of treatment (P = 0.02). All values remained
within normal ranges, however. Dexamethasone significantly decreased
PCV on day 14 and total proteins on days 14 and 21 compared to day 0.
On day 21, total proteins were significantly lower in dexamethasone-
treated horses compared to those treated with 1687.5 and 2700 lg
(device with nozzle A) of ciclesonide. Ciclesonide did not alter significantly
any of the blood parameters studied (Table 2).
The most commonly observed AE was ocular irritation and discharge (six
episodes in five horses, of which five during ciclesonide treatment and one
during post ciclesonide treatment week). More details are available online.
Study III
DPL, RL, EL, and weighted clinical score significantly decreased on day 7
and 14 compared to day 0 only with 2700 lg ciclesonide twice daily. A
TABLE 1: Haematology and blood biochemistry findings in study I
Ciclesonide
450 lg
Ciclesonide
900 lg
Ciclesonide
1800 lg Dexamethasone
PCV [%]
Day 0 36  4 37  5 36  7 36  7
Day 14 35  4 34  6 34  6 37  5
Day 21 37  5 36  5 35  6 35  5
Total proteins [g/L]
Day 0 75.1  7.3 75.6  6.9 72.6  9.0 74.9  7.4
Day 14 73.9  6.1 74.4  4.7 71.9  6.4 72.4  2.3
Day 21 75.2  7.12 75.1  6.62 72.0  08.9 65.7  2.81
WBC [9109/L]
Day 0 7.1  1.6 7.5  1.1 7.1  1.6 7.3  1.5
Day 14 7.3  2.0 6.9  1.4 7.8  1.6 8.3  1.7
Day 21 8.1  1.8 7.3  2.8 7.4  1.0 6.5  1.6
Segmented neutrophils [9109/L]
Day 0 4.7  1.3 5.2  1.1 4.6  1.3 4.8  1.3
Day 14 5.0  1.7 4.4  1.1 5.4  1.7 6.2  1.3
Day 21 5.5  1.5 4.9  2.5 9.4  1.1 4.3  1.2
Lymphocytes [9109/L]
Day 0 2.0  0.4 1.8  0.3 1.9  0.5 2.1  0.7
Day 14 2.0  0.4 2.0  0.5 2.0  0.6 1.7  0.51
Day 21 2.2  0.52 1.9  0.3 2.1  0.6 1.8  0.4
Data presented as mean  s.d. PCV, packed cell volume; WBC, white
blood cells.
1Different from the same treatment at day 0 (P≤0.002).
2Different from dexamethasone at the same time point (P≤0.007).
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significant reduction in RL was also observed after 14 days of treatment
with 3712.5 lg ciclesonide administered once in the evening. On day 14,
values of DPL, RL, EL, and weighted clinical score of all ciclesonide-treated
horses were significantly lower compared to those observed in the
placebo-treated animals. (Fig 4a, b, c, and Supplementary Item 2c). At the
end of the study period, N-butyl-scopolamine administration significantly
reduced DPL, RL, and EL in all horses (Supplementary Item 3d–f). When
horses were arbitrarily classified as having mild, moderate, and severe
obstruction based on RL (1.0–1.8, 1.8–2.5, and >2.5 cm H2O/L/s,
respectively) and not accounting for repeated measures, a score ≥15
identified horses with severe obstruction with 70% sensitivity and 62%
specificity. Horses with moderate-to-severe airway obstruction were
correctly identified with a score ≥11 with 82% sensitivity and 70% specificity.
The weighted clinical score employed is a good predictor of RL during
disease exacerbations (Fig 5).
None of the treatments tested significantly decreased serum cortisol
(Fig 4d). During ciclesonide treatment, four horses accounted for seven
(out of 56) cortisol measures below the normal level (three horses during
treatment B, on days 0, 5, 7; and two horses during C, on days 5–7–10 and
14). During placebo, two horses accounted for four cortisol measures
below the normal level (on days 7 and 10–17–21). Treatment did not
significantly affect plasma protein concentration, PCV, WBC, neutrophils,
and lymphocytes counts (Table 3).
Adverse events consisted mainly of epiphora and pruritus. Except for
epiphora, that was observed in five horses during ciclesonide treatments
(six observations) and in two horses (two observations) during placebo/
post treatment/washout, the AE were equally observed during ciclesonide
treatments or placebo/post treatment/washout weeks. Additional details
are provided online.
Three out of seven horses achieved RL normalisation (RL<1 cm H2O/L/s)
after 14 days of 2700 lg ciclesonide twice daily. Only 2/7 horses reached
RL normalisation with 3712.5 lg ciclesonide once in the evening, and 0/7
when the same dose was administered in the morning. The number of
horses achieving RL normalisation 20 min after N-butyl-scopolamine-
induced bronchodilation was 2/7.
Discussion
Inhaled corticosteroids improve the lung function during experimentally
induced exacerbations in asthmatic horses [1,3,4,6,7]. However, their use
in horses is off-label and all formerly used inhaled corticosteroids
significantly decrease serum cortisol [1,9]. Having inhaled corticosteroids
for use in horses with an improved safety profile would be suitable for
prevention and treatment of equine asthma and related conditions [1]. The
present studies investigated for the first time the effects of increased doses
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Fig 3: Study II. Lung function a), b), weighted clinical scores c), and serum cortisol d) of horses administered oral dexamethasone (DEX) or inhaled ciclesonide (CIC) at
different doses and/or devices a) vs. b). Data are presented as means and s.d. a), b), d) or interquartile ranges and mix-to-max values c) across eight horses at each day.
RL, respiratory resistance; EL, respiratory elastance.
§Different from day 0 for the same treatment (P≤0.003); *Different from dexamethasone at the same time point
(P<0.0001).
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of inhaled ciclesonide on lung function, clinical signs related to airflow
limitation, and serum cortisol levels in asthmatic horses. The first
experiment was designed as a dose-titration study; we then indirectly
investigated the effects of a shortened drug delivery time (asthma-adapted
nozzle, study II) and of different administration frequencies/time (study III).
Our results indicate that ciclesonide reverses airway obstruction in horses
with asthma, with a favourable safety profile. Indeed, serum cortisol was
not significantly affected by ciclesonide administration at any of the doses
tested.
Ciclesonide is a pro-drug, enzymatically hydrolysed to a pharma-
cologically active metabolite desisobutyryl-ciclesonide (des-CIC) following
inhalative application by carboxylesterases present within the bronchial
epithelial cells. Des-CIC has anti-inflammatory activity with affinity for the
glucocorticoid receptor that is 100–120 times higher than the parent
compound. The anti-inflammatory effects of des-CIC in human asthma are
thought to be primarily mediated via inhibition of tumour necrosis factor-
alpha and the Th-2 cytokine interleukin-4 in airway epithelial cells [12], two
cytokines implicated in the pathogenesis of equine asthma [20,21]. The
maximal dose of ciclesonide to be tested in the first study was based on
the clinical equivalence observed in human patients between fluticasone
propionate and ciclesonide (80 lg of ciclesonide are considered clinically
equivalent to 100 lg of fluticasone [22]) and on previous experiments
performed in horses during which fluticasone propionate was shown to be
effective at doses ≥2000 lg/day [1,3,4]. The decision to test lower doses
initially was made to determine the minimal effective dose for treating
asthmatic horses. Study III suggests that administration of 2700 lg
ciclesonide twice daily might be the most effective dose of the treatment,
with significant RL reduction already at day 7 compared to day 0, and with
no differences noticed with the other tested doses. Although ciclesonide
TABLE 2: Haematology and blood biochemistry findings in study II
Ciclesonide
1687.5 lg
Ciclesonide
2700 lg (A)
Ciclesonide
2700 lg (B) Dexamethasone
PCV [%]
Day 0 34  4 35  5 34  3 36  4
Day 14 32  5 32  4 32  4 31  41
Day 21 34  4 33  5 34  4 35  4
Total proteins [g/L]
Day 0 71.8  6.4 71.6  8.0 70.6  3.7 75.1  6.3
Day 14 70.8  5.1 70.1  4.1 69.3  4.9 69.8  3.61
Day 21 73.0  4.52 71.5  5.82 70.4  6.3 65.5  3.81
WBC [9109/L]
Day 0 6.8  2.2 7.4  2.0 6.49  1.4 7.4  1.9
Day 14 7.6  2.8 7.5  1.7 7.0  2.0 8.3  1.8
Day 21 7.1  2.2 6.8  2.2 7.2  2.0 7.0  1.1
Segmented neutrophils [9109/L]
Day 0 4.5  1.6 4.9  1.4 4.2  1.2 4.8  1.5
Day 14 5.2  2.5 4.8  1.1 4.7  2.0 6.2  1.4
Day 21 4.5  1.8 4.4  1.7 4.8  1.5 4.8  1.0
Lymphocytes [9109/L]
Day 0 1.9  0.5 2.0  0.6 1.8  0.4 2.1  0.6
Day 14 1.9  0.3 2.1  0.4 1.7  0.4 1.7  0.6
Day 21 2.0  0.4 2.0  0.4 2.0  0.6 1.7  0.3
Data presented as mean  s.d. PCV, packed cell volume; WBC, white
blood cells.
1
Different from the same treatment at day 0 (P≤0.002).
2
Different from dexamethasone at the same time point (P≤0.002).
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Fig 4: Study III, Lung function a), b), weighted clinical score c), and serum cortisol values d) of horses administered inhaled placebo or ciclesonide (CIC) at different doses
and frequency. In a) and c), horses were subjectively classified as having severe, moderate, or mild airway obstruction based on RL and weighted clinical score. Data are
presented as interquartile ranges and mix-to-max values in a)–c) and as means and s.d. d) across eight horses at each day. EL, respiratory elastance.
§Different from day
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induced significant amelioration of the lung function, especially at the
highest doses tested, RL normalisation was not reached in all subjects. The
same was observed with dexamethasone, most likely because inhibition of
some of the factors causing obstruction (i.e. mucus hypersecretion,
bronchial remodelling) may take >14 days.
Ciclesonide is characterised by low oral bioavailability (<1%) and low
systemic exposure. It displays high plasma protein binding (~99% vs. 71–
98% of most ICSs) and rapid systemic clearance. As systemic side effects of
inhaled corticosteroids result from the interaction of unbound systemically
available fraction of inhaled corticosteroids with glucocorticoid receptors
expressed by non-pulmonary cells, ciclesonide has an excellent safety
profile [12]. Suppression of endogenous cortisol levels following inhaled
corticosteroid therapy is indicative of an effect on the hypothalamic–
pituitary–adrenal axis and represents undesired systemic activity.
Prolonged ciclesonide treatment did not suppress serum cortisol levels in
our study. Cortisol levels below normal ranges were occasionally detected
in placebo and ciclesonide-treated animals. Whether this was due to
cumulative cortisol suppression [23], to circadian hormonal variation, or to
other causes remains undetermined.
Significant reduction in RL on day 7 was observed with ciclesonide
doses ≥2700 and ≥1687.5 lg twice daily when nozzle A and B were used,
respectively. Similar outcomes were observed for EL, suggesting an
effective deposition of ciclesonide throughout the bronchial tree with both
nozzles, but a possibly improved performance of nozzle B, despite no
significant differences were noted when nozzles were directly compared
at the same drug dosage. The effects of ciclesonide 2700 lg twice daily
on RL and weighted clinical score were observed on day 7 in horses with
mild-to-severe airflow obstruction, with ≥30% improvement even in horses
showing mild airflow limitation. Ciclesonide 3712.5 lg once daily
significantly improved RL only when delivered in the evening. A significant
effect of dosage timing on drug efficacy is reported for other inhaled
corticosteroids, with evening administration showing better results [24].
Ciclesonide effect on lung function was lost 1-week after discontinuation
of the therapy. Contrarily, weighted clinical score improvement remained
significant up to 1-week post treatment in horses receiving ciclesonide
2700 lg twice daily and dexamethasone in study II. This discrepancy
could be due to the exacerbation-related development/worsening of air
trapping in the horses’ lungs, which might prevent the transmission of
lung sounds during auscultation, falsely reducing the scores in this phase.
Alternatively, the score parameters not directly related to lung resistance
(e.g. nasal discharge, coughing, and tracheal sounds) might have
introduced a bias. Overall, however, the 23-point weighted clinical score
allowed the identification of horses experiencing airway obstruction in
most cases and was able to predict the degree of airflow obstruction
(mild/moderate vs. severe) with 82% sensitivity and 70% specificity. These
findings indicate that the clinical score employed can be applied clinically
and can serve as a practical tool for the practitioners to monitor airway
dysfunction.
Ciclesonide was administered using a device composed of a soft mist
inhaler core based on Respimat technology, and an adaptor for the horse
nostril comprising a respiration indicator in the chamber wall, which
facilitates the identification of the breathing phases of the horse by
deflection. The soft mist inhaler forces a metered dose of the drug solution
through a nozzle, producing two fine jets of liquid that converge at a
preset angle generating the soft mist. The advantages of the soft mist
inhaler are: the high fine particle fraction (~65–80% particles <5 lm; this
fraction can reach the small airways and alveoli), the slow velocity of
ejection of the soft mist, and the consequent relatively long generation
time of the aerosol cloud. Altogether, these factors result in larger
amounts of the drug delivered to the lungs [25]. In this study, two different
nozzles were tested with slight differences in clinical outcomes. It was
noticed that when the horses’ respiratory rate exceeded 30 bpm, the
inspiratory time was too short for the delivery time of the inhaler.
However, thanks to the inhaler design, most of the released ciclesonide
remained available in the chamber, for inhalation during subsequent
breathing cycles.
In summary, 1-week treatment with inhaled ciclesonide significantly
improved lung function and clinical signs of horses with equine asthma in
exacerbation, without suppressing serum cortisol. Overall, the effect on
lung function and clinical signs of airway obstruction remain constant from
day 7 to day 14 of treatment. Maximal clinical effects are observed with
2700 lg of ciclesonide administered twice daily in horses with
experimentally induced equine asthma exacerbations.
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TABLE 3: Haematology and blood biochemistry findings in study III
Placebo
Ciclesonide
2700 lg
Ciclesonide
3712.5 lg am
Ciclesonide
3712.5 lg pm
PCV [%]
Day 0 34  5 35  4 35  2 35  4
Day 14 34  5 34  3 34  4 34  5
Day 21 32  4 33  3 36  4 33  5
Total proteins [g/L]
Day 0 68.2  2.4 69.7  3.1 71.1  3.6 69.9  3.7
Day 14 71.1  2.3 69.7  2.8 69.4  3.9 68.0  4.2
Day 21 70.0  2.0 67.1  3.4 69.0  4.2 68.0  3.6
WBC [9109/L]
Day 0 6.7  0.8 6.8  0.6 6.9  1.0 6.6  1.3
Day 14 7.0  1.5 7.4  1.6 7.3  1.2 7.2  1.1
Day 21 6.7  1.3 6.3  1.0 6.8  1.3 6.3  0.8
Segmented neutrophils [9109/L]
Day 0 4.1  1.0 4.0  0.8 4.4  1.0 3.7  1.2
Day 14 4.3  1.3 4.6  1.4 4.4  1.0 4.4  1.2
Day 21 3.9  1.1 3.5  0.8 3.7  1.1 3.4  0.7
Lymphocytes [9109/L]
Day 0 2.3  0.5 2.5  0.6 2.2  0.3 2.5  0.4
Day 14 2.3  0.2 2.5  0.6 2.5  0.5 2.4  0.3
Day 21 2.5  0.3 2.5  0.5 2.7  0.5 2.5  0.3
Data presented as mean  s.d. PCV, packed cell volume; WBC, white
blood cells.
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